Immunic, Inc.
NASDAQ:IMUX
Overview | Financials
Company Name | Immunic, Inc. |
Symbol | IMUX |
Currency | USD |
Price | 1.18 |
Market Cap | 106,293,220 |
Dividend Yield | 0% |
52-week-range | 0.945 - 2.11 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Daniel Vitt Ph.D. |
Website | https://www.immunic-therapeutics.com |
An error occurred while fetching data.
About Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD